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Abstract: Human mesenchymal stem cells (hMSC) can be expanded in vitro and differentiated towards osteogenic, chondrogenic 
or adipogenic lineages, making them an attractive source for tissue engineering and regenerative medicine. Chitinase-like-proteins 
(CLPs) belong to the family 18 glycosyl hydrolases and are believed to play a role in inflammation and tissue remodelling. The aim 
of this study was to determine the effect of the aminosugar glucosamine on the expression of the CLP YKL-40 during osteogenic 
differentiation of hMSC. Glucosamine did not affect multipotency of hMSC nor proliferation rate of undifferentiated hMSC.  
YKL-40 was expressed during both expansion of undifferentiated hMSC and during osteogenic differentiation. A slight but non-
significant increase in YKL-40 expression was observed with glucosamine, accompanied by a pH-dependent delay in mineralization.
However, glucosamine induced higher expression of osteogenic marker genes. 
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Introduction 
Stem cells hold a great promise as a tool in basic research 
and development of drugs and new treatments in regenerative 
medicine. Human multipotent mesenchymal stromal cells 
(hMSC) is a commonly used term for a heterogeneous  
population of cells that can be derived from human bone  
marrow, adipose tissue, peripheral blood or umbilical cord 
blood1,2. These cells can differentiate into cells of the  
mesenchymal lineage, e.g. to osteoblasts, chondrocytes,  
fibroblasts and adipocytes, as well as, stromal cells of the bone 
marrow3. 
In connection to the regeneration of the osteogenic matrix, 
chitinases and chitinase-like-proteins (CLP) have been  
suggested to have a role in defence mechanisms against chitin-
containing particles or organisms and to participate in tissue 
remodelling and inflammation4,5. Whether triggering of the 
immune response and the potential role in tissue remodelling is 
directly affected by the chitinase-like-proteins or dependent on 
the downstream induction of cytokines and growth factors has 
not been investigated5. There have been indications that the 
chitinase-like-proteins are expressed during tissue damage or 
regeneration in an attempt to counter the negative effect of 
inflammatory cytokines6. In humans, three chitinase-like-
proteins are known, YKL-39, YKL-40 and oviductin, as well 
as the active chitinases acidic mammalian chitinase (AMCase) 
and chitotriosidase7. The active chitinases belong to the family 
18 glycosyl hydrolases, the same family as the CLPs. CLPs 
have lost the ability to degrade chitin due to an amino acid 
substitution in the binding cleft7,8, but the ability to bind chitin 
and chitooligosaccharides is still retained9. Binding of the  
ligand induces a large conformational change in YKL-40 
which indicates a potential signalling role of the enzyme10. 
YKL-40 is expressed by articular chondrocytes, synoviocytes, 
osteoblasts and differentiated macrophages and is up-regulated 
in inflammatory diseases like rheumatoid arthritis and  
osteoarthritis6,11. YKL-40 expression has been suggested to be 
regulated by the transcription factor NF-Beta6. Also, it has 
been proposed that YKL-40 might prevent damage to the  
extra-cellular matrix during inflammation by reducing the 
deleterious effect of pro-inflammatory cytokines12. 
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Due to chitinases, chitin, the second most abundant  
compound in nature, does not accumulate in the environment13. 
Chitin, a structural component in the cell wall of crustaceans 
and fungi, can be used for the production of glucosamine, 
chitooligosaccharides and chitosan, which have wide ranging 
uses in biotechology, agriculture and food science13.  
Glucosamine is an aminosugar that naturally occurs in the 
body and has been claimed to have beneficial effects on  
osteoarthritis as it constitutes one of the subunits in  
glycosaminoglycans found in the extra-cellular matrix of  
cartilage14. It is unknown how glucosamine might work to 
ameliorate arthritis, but a connection to nitric oxide production 
has been suggested14,15. The effect of glucosamine on bone 
resorption and remodelling has been evaluated in a  
collagenase-induced osteoarthritis model in mice16. It was 
shown that excessive bone formation and bone remodelling 
were reduced and bone resorption was decreased16. The effect 
of glucosamine on the CLPs and its role during osteogenesis of 
hMSC has not been investigated. 
In this study, we show that the chitinase-like-protein YKL-40
is expressed in hMSC and is maintained during osteogenic 
differentiation of these cells. The effect of glucosamine on the 
expression of YKL-40 and osteogenic differentiation was  
analysed. 
 
Results and Discussion 
hMSC Morphology and Proliferation. Short-term  
expansion of cells (single passage) in control media and  
glucosamine supplemented media did not lead to changes in 
the expression of cell surface markers and the cells comply 
with the characteristics of bone-marrow derived mesenchymal 
stromal cells (supplementary Figure 1)17. Cell morphology was 
typical of hMSC-small spindle-shaped cells attached to the 
surface of tissue culture plastic (Fig. 1A). Glucosamine did not 
affect cell attachment or morphology during expansion. During
osteogenic differentiation, cell morphology changed to a more 
cuboidal and flattened shape. In later stages of differentiation, 
osteoblastic cells deposited calcium hydroxyapatite crystals 
and cell layers pulled together. No difference in phenotype 
was observed in the presence of glucosamine, except for the 
lack of calcium deposition. 
Proliferation was similar during short-term expansion of 
hMSC in control media and glucosamine media, with a  
decrease in proliferation on days 5 and 7 (Fig. 1B). 
Furthermore, the cells could be successfully differentiated 
towards the osteogenic, chondrogenic and adipogenic lineage, 
proving multi-lineage potential (supplementary Fig. 2). 
 
Expression of the Chitinase-Like-Proteins (CLPs) in 
hMSC. CLPs have putative roles in defence mechanisms 
against chitin-containing particles and participate in tissue 
remodelling and inflammation4,5. Crystallography studies  
revealed that the enzyme can bind chitin and chitooligosaccha-
rides with high affinity9,10. We therefore examined, whether 
the aminosugar glucosamine could affect the expression of the 
CLPs during short-term expansion of hMSC. 
hMSC expressed the chitinase-like protein YKL-40 at day 3 
and day 7 during expansion (supplementary Fig. 3). No  
statistical difference was found between control samples (0.85 
± 0.85 fold increase over 7 days) and glucosamine treated 
samples (3.24 ± 2.17 fold increase over 7 days) in the  
expression of YKL-40. The active chitinases, chitotriosidase 
(CHIT1) and acidic mammalian chitinase (AMCase) were not 
detected (data not shown). 
During osteogenic differentiation, YKL-40 was expressed 
both in control (1.82 ± 0.53 fold increase over 28 days) and 
glucosamine treated samples (3.52 ± 0.63; p = 0.0828 fold 
increase over 28 days) (Fig. 2A). A trend in which glucosamine
increased YKL-40 expression during osteogenic differentia-
tion was observed, but statistical significance (p < 0.05) was 
not met. 
 
Osteoblast Gene Expression. The following osteogenic 
marker genes: alkaline phosphatase (ALP), osteocalcin (OCN), 
osteopontin (OPN) and runt-related transcription factor 2 
(RUNX-2) were expressed both in control and glucosamine 
treated samples during osteogenic differentiation (Fig. 2A). A 
statistically significant increase in the presence of glucosamine 
was observed for ALP (0.63 ± 0.24 fold increase in control vs. 
1.84 ± 0.13 fold increase in glucosamine; p = 0.0011), OCN 
(1.41 ± 0.41 fold increase in control vs. 2.85 ± 0.18 fold  
increase in glucosamine; p = 0.0087) and RUNX-2 (1.06 ± 
0.31 fold increase in control vs. 2.39 ± 0.17 fold increase in 
glucosamine; p = 0.0037) gene expression. The difference in 
OPN expression (0.20 ± 0.41 fold increase in control vs. 1.56 
± 0.62 fold increase in glucosamine; p = 0.097) was not  
statistically significant but a trend was observed that suggested 
glucosamine could increase the expression of OPN. 
To visualize the correlation between the expression of 
YKL-40 and the expression of the osteogenic marker genes, a 
heatmap was generated (Fig. 2B)18. Clustering divided the 
sample population into three distinct groups: (1) control  
samples from day 7 to day 25 of osteogenic differentiation; (2) 
glucosamine treated samples from day 7 to day 21; and (3) late 
osteogenesis including control samples at day 28 and  
glucosamine treated samples from day 25 to day 28. In the first 
 
Figure 1.  Effect of glucosamine on hMSC phenotype and 
proliferation. (A) Phenotype consistency in the expansion and 
osteogenic differentiation of hMSC (representative pictures); 
(B) Proliferation of hMSC grown in control media and media 
supplemented with 200 µg/mL Glucosamine. Bars illustrate 
proliferation on days 1, 3, 5 and 7 (n = 42 measurements). 
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group overall expression of genes was low, except for the  
expression of OPN. The second group, i.e. early glucosamine 
treated samples, showed high expression of all osteogenic 
genes but only intermediate expression of YKL-40. Late  
osteogenesis, the third group, was characterized by peak  
expression of YKL-40 as well as OCN, RUNX-2 and ALP, 
but lower expression of OPN. 
The increased expression of YKL-40 was correlated to the 
increased expression of the osteogenic marker genes, with the 
exception of OPN, which was highest in early glucosamine 
treated samples (Fig. 2B). Correlation was determined by cal-
culating the Spearman correlation coefficient (r2), which was 
shown to be 77.64% for YKL-40/RUNX-2, 90.45% for 
ALP/RUNX-2 and 78.87% for OCN/RUNX-2. Visualization 
by means of a heatmap suggested furthermore that glucosa-
mine might modify osteogenic gene expression to match late  
osteogenesis compared to control samples. How and why  
glucosamine is affecting the expression of YKL-40 during 
long-term cultures was not investigated. 
Our data suggest that YKL-40, in combination with  
increased expression of ALP, RUNX-2 and OCN, could play a 
role during late osteogenic differentiation of hMSC and this 
process could be modified by glucosamine, a subunit of the 
natural substrate for chitinases. YKL-40 is known to take part 
in tissue remodelling and regeneration but also protects the 
tissue from negative effects of pro-inflammatory cytokines12. 
This indicates that up-regulation of YKL-40 in developing and 
regenerating tissues might benefit the remodelling process. 
 
Mineralization. Control cells increased the amount of  
mineralization deposited over a period of 28 days, as shown in 
von Kossa staining (Fig. 3A). Glucosamine treatment resulted 
in an overall impairment of mineral deposition with the first 
deposits visible after 21 days. Alizarin Red Staining showed 
the typical increase of calcium deposition expected in control 
cultures, whereas glucosamine supplemented cells did not 
show any sign of calcification (Fig. 3B). Photometric  
evaluation of Alizarin Red Staining visualized the lack of  
calcification in the presence of glucosamine, while control 
cells mineralized from day 21 onward (data not shown). 
A likely explanation for the lack of mineralization in  
glucosamine supplemented cultures could be acidosis of the 
cell culture media. All glucosamine stock solutions were  
prepared in PBS, but when the final concentration of  
glucosamine was added to the cell culture media, a pH change 
of the media was observed. Acidosis has been shown to delay 
mineralization in hMSC-derived osteoblasts and to increase 
OCN and RUNX-2 expression as well as decrease ALP,  
osterix (OSX) and OPN gene expression19. However, acidosis, 
as shown by Disthabanchong et al., does not explain the effect 
of glucosamine on gene expression observed in the present 
study, apart from the delay in mineralization in hMSC19. ALP 
mRNA expression and activity have been shown as well by 
other groups to be increased in the presence of glucosamine, 
when pH was stabilized at 7.420. Furthermore, when media pH 
was adjusted using sodium bicarbonate solution in our study, 
 
Figure 2.  Effect of glucosamine on gene expression during 
osteogenic differentiation of hMSC. (A) Average expression 
of YKL-40, Alkaline Phosphatase (ALP), Osteocalcin (OCN), 
Osteopontin (OPN) and runt-related transcription factor 2 
(RUNX-2) in control (white bars) and glucosamine (black bars) 
supplemented cultures over a period of 28 days of osteogenic 
differentiation. Bars describe average fold change with stand-
ard error. n = 2; * = p < 0.05; (B) Heatmap and hierarchical 
clustering of gene expression data auto-scaled to genes. Red 
colour depicts high expression and green colour depicts low 
expression (n = 2). 
 
Figure 3.  Characterization of mineralization processes during 
osteogenic differentiation of hMSC. (A) von Kossa Staining of 
hMSC differentiated for 28 days towards the osteogenic 
lineage. Dark brown colour is indicative of mineralization. (B) 
Alizarin Red Staining of hMSC differentiated for 28 days 
towards the osteogenic lineage. Dark red colour is indicative of 
calcification. Pictures are representative from 9 experiments. 
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delay in mineralization was resolved (data not shown). 
 
Effect of Glucosamine on Cytokine Expression. Whether 
the influence of YKL-40 on the activation of the immune  
system and the tissue remodelling process is due to the proteins
themselves or the secondary induction of growth factors and 
cytokines is not known5. Furthermore, increased levels of 
YKL-40 are believed to protect the tissue from the negative 
effects of pro-inflammatory cytokines6. Therefore, we  
determined the secretion of several pro- and anti-inflammatory 
cytokines and growth factors during the osteogenic  
differentiation of hMSC. 
No secretion of IL-1, IL-12p (40), EGF and RANTES was 
observed in control cells or glucosamine supplemented cells. 
The anti-inflammatory cytokines IL-4 (3.9 ± 2.4 pg/mL in 
control vs. 3.5 ± 2.0 pg/mL in glucosamine), IL-10 (8.0 ± 3.5 
pg/mL in control vs. 7.3 ± 1.1 pg/mL in glucosamine) and  
TNF- (16.5 ± 6.9 pg/mL in control vs. 15.1 ± 6.4 pg/mL in 
glucosamine) were secreted in low amounts over 28 days of 
osteogenic differentiation (Fig. 4A). The growth factor VEGF 
(174.5 ± 133.1 pg/mL in control vs. 390.7 ± 27.7 pg/mL in  
glucosamine) showed intermediate secretion and the inflam-
matory cytokines IL-6 (1725.6 ± 307.3 pg/mL in control vs. 
1321.9 ± 538.2 pg/mL in glucosamine) and IL-8 (344.6 ± 
133.1 pg/mL in control vs. 390.7 ± 165.4 pg/mL in glucosa-
mine) showed high secretion (Fig. 4B). The differences in 
secretion levels between control samples and glucosamine 
treated samples were not statistically significant with any of 
the cytokines determined. 
 
Experimental Section 
Cell Culture. Human, bone-marrow-derived, mesenchymal 
stromal cells (hMSC) (Lonza, Basel, Switzerland) were  
cultured in Standard Mesenchymal Stem Cell Basal media 
(Lonza) supplemented with L-Glutamine, Gentamicin Sulfate/
Amphotericin, and hMSC growth supplement following  
manufacturer’s instructions. For osteogenic differentiation, 
Differentiation Basal Medium Osteogenic (Lonza)  
supplemented with dexamethasone, ascorbate, L-Glutamine, 
Streptamycine/Penicilline, -Glycerophosphate and hMSC 
growth supplement was used. MTT proliferation assays were 
performed in DMEM/F12 media (Gibco, Carlsbad, California, 
USA) supplemented with Penicillin/Streptomycin (Invitrogen) 
and 10% hMSC-approved fetal calf serum (Stem Cell,  
Vancouver, BC, Canada). To determine the effect of  
glucosamine on hMSC, standard media and osteogenic  
differentiation media were supplemented with 200 µg/mL D-
glucosamine hydrochloride-salt (YSKYaizu Suisankagaku 
Industry, Shizuoka, Japan). Glucosamine stock solutions were 
prepared by dissolving glucosamine in sterile PBS and filtered 
through 0.45 µm and 0.22 µm filters.  
To prove multi-lineage differentiation potential, unstimulated
cells were differentiated towards the osteogenic, chondrogenic 
and adipogenic lineage after appropriate expansion. All  
experiments were done at minimum in triplicate and hMSC 
from passage 3–5 were used in all experiments. 
 
MTT Proliferation Assays. hMSC were expanded in a  
96-well-plate and proliferation determined with the ATCC 
MTT proliferation kit (ATCC Bioproducts, Boras, Sweden) 
following manufacturer‘s instructions. 
 
RNA Isolation and cDNA Transcription. RNA isolation 
was performed using Qiagen BioRobot workstation (Quiagen, 
Hilden, Germany) and the EZ-1 RNA Cell Mini Kit (Qiagen), 
following manufacturer’s instructions. High-Capacitiy cDNA 
Reverse Transcription Kit from Applied Biosystems (Foster 
City, California, USA) was used in all experiments. 
 
Gene Expression. To quantify gene expression of selected 
genes, qPCR was performed in a StepOne Real Time PCR 
System (Applied Biosystems). 10 µL aliquots of Taqman  
master mix and 1 µL of Taqman assay (Applied Biosystems) 
were added to 9 µL of 1:10 diluted sample cDNA for each 
reaction.  
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was 
used as a reference gene. Taqman assays included YKL-40 
(Hs00609691_m1), acidic mammalian chitinase (AMCase) 
(Hs00757767_m1), chitotriosidase (CHIT1) (Hs00185753_m1),
osteocalcin (OCN) (Hs00609452_g1), osteopontin (OPN) 
(Hs00167093_m1), alkaline phosphatase (ALP) (Hs01029141_
g1) and runt-related transcription factor 2 (RUNX-2) 
(Hs00231692_m1), all from Applied Biosystems. 
Data were analysed using GenEX 5.3.2.13 software (MultiD 
Analyses, Gothenburg, Sweden). Data pre-processing was 
based on averaged qPCR repeats, normalized to the reference 
gene GAPDH and relative quantities were calculated relative 
to the earliest control sample (3 days expansion during  
short-term expansion and 7 days osteogenic differentiation of 
control samples for osteogenesis experiments). Graphs were 
created from averaged fold changes over 28 days relative to 
the respective control sample. 
 
Luminex 10Plex Human Cytokine Assay. Luminex 
10Plex Human Cytokine Assay (Panomics, Fremont, California,
USA) was performed using media supernatants from stimulated
and unstimulated cells during osteogenic differentiation. The 
following cytokines were analysed: Interleukin-1 (IL-1,  
IL-4, IL-6, IL-8, IL-10, IL-12 (p40), tumor necrosis factor- 
(TNF-), RANTES, vascular endothelial growth factor 
(VEGF) and epidermal growth factor (EGF) (detection limit of  
cytokines: 1.3 pg/mL). 
 
Figure 4.  Average cytokine secretion during osteogenic 
differentiation of hMSC in control media or glucosamine (200 
µg/mL) supplemented media. (A) Anti-inflammatory cytokines
IL-4, IL-10 and TNF-. (B) Inflammatory cytokines IL-6, 
IL-8 and growth-factor VEGF (average expression over 28 
days); error bars describe standard error; n = 2. 
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Alizarin Red Staining and Quantitation. Cells were 
washed with phosphate-buffered saline (PBS) and fixed in 4% 
paraformaldehyde. Next, cells were washed with distilled H2O 
(dH2O) and stained with a 2% Alizarin Red Solution (Sigma 
Aldrich Inc., St. Louis, MO, USA) in dH2O at pH 4.1 for 20 
min. Cells were then washed with dH2O and pictures were 
taken in a scanner (ScanJet ADF, Hewlett Packard).  
For quantification, dried and stained wells were hydrated 
over-night in dH2O and incubated with 10% cetyl-pyridinium 
chloride (Sigma) in dH2O for 15 min on a shaker. Cells were 
spun down and supernatant aliquots were analysed in a  
MultiSkan spectrometer (Thermo Scientific) at 562 nm. 
 
Von Kossa Staining. Cells were washed with PBS and 
fixed in 4% paraformaldehyde. Standard protocols were used 
to perform von Kossa staining and pictures were taken in a 
fluorescent microscope (Olympus BX51) using Cell A Imaging
Software (Olympus, Center Valley, PA, USA). 
 
Statistical Analysis. Data are presented as means and 
standard deviations, with the exception of gene expression 
data and cytokine secretion, where standard error was used. 
Statistical analysis was performed using GenEx 5.3.2.13  
software. To evaluate treatment effect, t-test was used and a 
heatmap based on hierarchical clustering was constructed from 
autoscaled, pre-processed relative fold changes. Correlation of 
gene expression data visualized in the heatmap set-up was 




In this study, we showed the expression of the chitinase-
like-protein YKL-40 in hMSC, both during expansion of  
undifferentiated cells and after osteogenic differentiation.  
Glucosamine did neither affect the maintenance of hMSC  
pluripotency nor proliferation. The active chitinases, chitotrio-
sidase (CHIT1) and acidic mammalian chitinase (AMCase), 
were not detected. Glucosamine increased the expression of 
YKL-40 during osteogenic differentiation, but did not affect 
expression during short-term expansion. Glucosamine was 
furthermore associated with an increase in the expression of 
osteogenic marker genes during osteogenic differentiation of 
hMSC. 
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